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A symposium, sponsored by the Cancer Research Campaign,
was held recently at The Beatson Institute for Cancer
Research in Glasgow to discuss cellular, molecular and
clinical aspects of squamous cell carcinoma (SCC). The




(iv) Invasiveness and metastasis
(v) Immune response and therapy.
Exciting aspects of the meeting were the identification of
novel molecules involved in the malignant process as well as
potential diagnostic/prognostic markers or targets for
immunological and pharmacological intervention. It is these
aspects of the symposium that will be highlighted in this
report.
Stem cells
The predicted target cells for malignant transformation of the
epidermis are the basal stem cells, since only these cells are
mitotically active and consequently susceptible to the effects
of chemical carcinogens. It has long been thought that the
region of the epidermal lining of the hair follicle in which the
stem cells are situated is an area at the base of the follicle
known as the bulb region. However, Robert Lavker (New
York) provided convincing proof that the stem cells are
actually located in the bulge region of the upper root sheath.
These cells are normally very slow-cycling, but during the
anagen phase of hair growth they undergo transient pro-
liferation. Interestingly, it is during anagen that the hair
follicle is particularly susceptible to chemical carcinogenesis
and cells from the bulge region grow better in culture than
cells from other areas, including the bulb. Taken together
these experiments have probably identified the true stem cell
population of the hair follicle and should have important
implications in the design and analysis of future skin
chemical carcinogenesis experiments.
Cell adhesion molecules andsmall cell carcinoma (SSC)
A recurring issue during the meeting was the role of cell
adhesion molecules in the development of cancer. It is clear
that these molecules are important in tissue organisation as
well as in various stages of malignant progression including
invasion and metastasis.
Once an epithelial cell leaves the basal stem cell layer it no
longer divides but begins to terminally differentiate. Fiona
Watt (London) addressed the issue of what determines how a
basal cell becomes committed to differentiation in preference
to cell division. Using FACS analysis two populations of
basal cells could be distinguished on the basis of the level of
integrin molecules they expressed. The first population ex-
presses high levels ofP1 integrin and has a high proliferative
capacity, while the second expresses lower levels of 1P integ-
rin and tends to differentiate. The propensity to form col-
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onies directly correlates with the level of integrin expression,
indicating that at least one of the critical steps in epithelial
stem cell commitment is the switching offof the expression of
a cell adhesion molecule. Interestingly, it has been reported
that expression of some integrin family members increases
during malignant conversion of mouse epidermal keratino-
cytes.
Merton Bernfield (Boston) outlined the importance of the
syndecans, a family of transmembrane proteoglycans that
mediate interactions of cells with the extracellular matrix
(ECM) and growth factors, in epithelial organisation. The
extracellular domains of the syndecans contain heparan sul-
phate chains, which interact with components of the ECM
such as fibronectin and collagens, while the cytoplasmic
domains contact the cytoskeleton. Their expression is tightly
regulated during development, differentiation and prolifera-
tion. Syndecans play a role in the maintenance of cell shape
and organisation and loss of syn-1 expression, by introduc-
tion of antisense RNA, leads to changes in mouse mammary
epithelial cells consistent with morphological transformation,
e.g. the cells become fusiform and have invasive properties in
collagen gels. Also, the major epithelial adhesion molecule
E-cadherin is down-regulated in these cells and some
tumours, such as those of the cervix, have reduced syndecan
expression.
A novel cytokine that has been identified in wound fluid
induces expression of syn-l in dermal mesenchyme and,
although much work remains to be done, it is clear that a
cytokine that regulates the expression of important cellular
regulators such as the syndecans could be of significant
therapeutic use.
Tumour metastasis is a major cause of death in cancer
patients and is an area of cancer research in which develop-
ment of therapeutics is vital. Metastasis is a multistep pro-
cess, and for a tumour cell to become fully metastatic it must
disseminate from the primary tumour, invade the surround-
ing tissue, enter the circulation and colonise distant sites. In
several presentations possible molecular steps involved in
tumour invasion and metastasis were discussed and, as may
have been suspected, changes in the expression of cell
adhesion molecules appear to be important in the invasive/
metastatic phenotype. Walter Birchmeyer (Essen) demon-
strated that the down-regulation of the epithelium-specific
cell adhesion molecule E-cadherin leads to increased motility
and invasiveness of carcinoma cells in vitro. Furthermore, in
SCC of the head and neck E-cadherin expression inversely
correlates with dedifferentiation of the tumour and the
presence of lymph node metastasis. Analysis of the E-
cadherin promoter indicates that it is inactive in dediffer-
entiated cells and this is probably because of the loss of
sequence-specific DNA-binding factors from these cells.
Amparo Cano (Madrid) showed that E-cadherin, P-cadherin
and 6a6p4 integrin expression is shut off while ac5,l integrin
expression increases during progression of SSC to the more
aggressive spindle cell phenotype. Elements in the P-cadherin
promoter that may be involved in the shut-off of expression
in spindle cells are presently being mapped.
Helmut Ponta (Karlsruhe) presented another example of
molecules with cell adhesive properties which are involved in
metastasis, namely CD44, a family of cell membrane glyco-
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proteins composed of splice variants differing in the exon
sequences in the extracellular domain of the protein. Splice
variants of CD44 have been identified that are not expressed
in non-metastasising tumour cells but are expressed in meta-
stases, and their expression confers metastatic behaviour on
locally growing tumour cells. Monoclonal antibodies recog-
nising the V6 epitope of CD44 variants have been developed,
and they have been used to show that benign colorectal
polyps have poor expression of CD44 and that expression
increases with progression to malignancy and metastasis. In
the breast, normal tissue is negative for the V6 epitope, while
74% of primary tumours and 100% of metastases are posi-
tive, therefore the absence of this epitope is a good prognos-
tic factor and may be of use in the clinical management of
this type of tumour.
Tumour-suppressor geneproducts and associatedproteins
In recent years a great deal of attention has been paid to the
role of tumour-suppressor gene loss in the development of
malignancy. Indeed p53 mutations are the most commonly
found genetic alterations in all cancers, and in the majority
of cervical tumours, in which p53 mutations are relatively
rare, the presence of human papillomavirus type 16 (HPV 16)
E6 protein ablates the normal cellular functions of p53 by
binding to it and causing its degradation. In normal cells p53
is rapidly turned over, however during periods of DNA
damage such as that caused by UV irradiation p53 levels are
increased and cells either go into G1 arrest to enable DNA
repair and cell survival to take place or, if DNA damage is
severe, cells apoptose and die. By this mechanism mutations
are not able to be propagated to future generations and p53
functions as a 'guardian of the genome'. Given the above, it
is not surprising that a large percentage of human tumours
have p53 mutations since inactivation of the p53 induction
pathway leads to genetic instability, a key step in malignant
transformation. David Lane (Dundee) is interested in the
identification of genes involved in the p53 response to DNA
damage. p53 is a sequence-specific DNA-binding protein that
can positively or negatively regulate target gene expression,
and Lane has shown that phosphorylation of p53 at its
carboxy terminus by casein kinase II converts latent p53 to
its DNA-binding form. This activity can be mimicked in vitro
by a p53 monoclonal antibody (PAb 421) or the heat shock
protein DNA K. Intriguingly, some p53 mutants can also be
activated to DNA-binding forms by similar treatments, rais-
ing the exciting possibility that small molecules could be
engineered which are capable of reactivating p53 mutants to
functional molecules in vivo either to kill tumour cells or to
stop them proliferating. This is an area that will doubtlessly
receive much attention in the future.
The E7 oncoprotein of HPV-16 also binds the product of a
tumour-suppressor gene, namely the retinoblastoma (Rb)
protein, and it is well documented that E7 is thought to
induce the expression of genes involved in DNA replication
by releasing the transcription factor E2F from a complex
with Rb. Karen Vousden (London) has identified the B-myb
gene as a target for E7 transcriptional activation. The exact
function of B-myb is not known, but it is regulated in a cell
cycle-specific manner such that it is expressed immediately
prior to S-phase, in a similar fashion as proteins involved in
DNA synthesis, and antisense B-myb transcripts have been
shown to inhibit the growth of mouse fibroblasts. E2F bind-
ing sites are present in the promoter of the B-myb gene, but
E2F bound to these sites does not appear to interact with Rb
protein, although the closely related p107 protein does. Also,
mutant E7 proteins that are unable to bind p107 lose the
ability to transactivate the B-myb promoter, while mutants
retaining the ability to bind p107 do not. Presumably B-myb
will be the first of many S-phase-specific genes to be
identified as targets of HPV E7 transactivation.
The early gene product of Ela is the adenovirus analogue
of HPV-16 E7 and, as such, it binds Rb and releases E2Fto
disrupt normal cell growth control mechanisms. Elizabeth
Moran (Cold Spring Harbor) described a protein, p300,
which also specifically interacts with Ela, is required for full
Ela-stimulated proliferation and which has transcriptional
regulatory functions. It is a sequence-specific DNA-binding
protein, and antibodies to the TATA-binding factor co-
precipitate p300, which is presumably intimately involved in
the regulation of the basal transcription machinery. Although
the functions of p300 largely remain to be identified, it is
likely to represent a major pathway through which Ela alters
cellular growth control.
Identification ofnovel oncogenes
Genetic alterations that increase expression or activate cer-
tain growth regulatory genes play a crucial role in the step-
wise progression to malignancy. Genes for growth factors or
their receptors fall into this category, and Stuart Aaronson
(Bethesda) has developed a cDNA expression cloning system
which will be of enormous potential in identifying novel
oncogenes and growth-regulatory molecules that may be
missed by more conventional genomic transfer protocols. The
technique involves the generation of a phagemid vector
cDNA expression library from tumour cells in which no
known activated oncogenes have been identified and its
transfection into normal cells in culture. DNA is isolated
from resulting foci and cDNA isolated by phagemid rescue.
Using this technique Aaronson and his collaborators have
isolated both known and novel growth factor, growth factor
receptor and transducer genes including the receptor for
keratinocyte growth factor (KGF), and a known G-protein
not previously linked to oncogenic transformation has been
identified as a candidate for further investigation in the
development of Ewing's sarcoma.
Gordon Peters (London) has studied the cyclin Dl gene,
which is located on human 1Iq13, a region that is amplified
in a large proportion of squamous cell carcinomas of the
head, neck, lung and oesophagus, resulting in an oyerexpres-
sion of cyclin DI. The exact function of cyclin 1 is not
known, but it is thought to be a Gl cyclin as it rescues yeast
deficient at this phase of the cell cycle. In an attempt to
understand the role of cyclin Dl in squamous cell carcinoma,
Peters and his colleagues have investigated its interaction
with cyclin-dependent kinases (CDKs). Immunoprecipitation
experiments have indicated that cyclin Dl interacts with
different CDKs in an SSC cell line (CDK4 and CDK6)
compared with primary human fibroblasts (CDK2 and
CDK5). Substrates for these kinases remain to be identified,
and work is currently being carried out to establish whether
the differences observed in the association with CDKs reflects
differences in the growth properties of tumour vs normal
cells.
Immune response
It is well known that the immune system plays an important
role in the body's defence against cancer. For example, UV-
induced murine skin cancers are highly antigenic and can
only be propagated in immunosuppressed hosts. Margaret
Kripke (Houston) discussed her interest in the mechanisms
underlying UV alteration of immune response. If T lympho-
cytes are removed from a UV-irradiated mouse and injected
into a second non-irradiated mouse, the recipient becomes
susceptible to UV-induced tumour formation, suggesting that
suppressor T cells are involved in this immunosuppression.
Also, culture medium taken from in vitro-irradiated keratino-
cytes contains a factor that renders mice susceptible to UV
carcinogenesis, suggesting that a cytokine is involved in
inducing the suppressor T cells involved. Evidence was pre-
sented that UV-induced DNA damage is the initiating event
in photoimmunosuppression. Increasing DNA repair by
administering T4 endonuclease V encapsulated in liposomes
to the skin of irradiated mice abrogated the suppression of
T-cell-mediated immunity. Undoubtedly efforts are being
made to characterise this putative cytokine.
Natural infection with human papillomaviruses (HPVs)
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which, in immunocompetent individuals, normally regress.
Understanding the immunobiology of HPV infection is vital
for the development of prophylactic or therapeutic interven-
tion strategies. Margaret Stanley (Cambridge) described an
animal model for studying the immunological events which
occur during spontaneous rejection of HPV-16-induced
warts. The technique involves grafting keratinocytes express-
ing HPV-16 oncogenes onto the backs of immunocompetent
host mice. The grafts grow as differentiated epithelia and
naturally regress after about 2 weeks. The regression can be
accelerated by challenging the mice specifically with E7
antigen in what appears to be a delayed-type hypersensitivity
response mediated by CD4+ cells. Since regression of human
cutaneous warts is accompanied by infiltration of CD4+
lymphocytes, the presentation of HPV antigen by the
epithelial route employed in these studies appears to provide
an accurate model in which the immunobiology of HPV
infection can be dissected and which may be of use in the
development of immunotherapeutic vaccines against HPV-
induced cancer.
Perhaps the most exciting prospect for immunotherapy of
cancer is adoptive transfer of cytotoxic T cells (CTLs). CTLs
recognise peptide sequences presented by MHC class 1
molecules on the surface of all cells, and in combination with
interleukin 2 (IL-2) they have been shown to eradicate large
tumour masses in mice. CTLs can be cultured from tumour
infiltrating lymphocytes; however, some tumours are poorly
immunogenic, and this procedure may not always work.
Cornelis Melief (Leiden) presented an attractive alternative
approach to this problem. Empty MHC-class I molecules
expressed on the surface of murine mutant lymphoma cells
can be stabilised by presenting them with peptides. This
system allows for the identification of T-cell epitopes within a
protein of choice and also the sensitisation of target T cells
for use in immunotherapy. Using overlapping peptides corre-
sponding to the HPV-16 E7 oncoprotein an E7 peptide
sequence has been identified that stimulates a T-cell response,
and immunisation with this peptide protects mice from
tumour formation when challenged with HPV-expressing
tumour cells.
Clearly this technique has enormous potential in the
immunotherapy of virally induced disease as well as cancers
of varying origins. CTLs have now been generated from
peptides derived from various oncogenic proteins, including
p53 and ras, and their therapeutic potential, although enor-
mous, remains to be shown.
Potential therapeutics
As mentioned earlier in this report, treatment of tumour
metastasis is vital if effective anti-cancer regimens are to be
achieved. A crucial property of invading tumour cells is the
ability to degrade the ECM and underlying basement mem-
brane. Many proteases have been implicated in tumour
invasion, one class of which, the metalloproteases, was the
subject of Mark Sobel's (Bethesda) presentation. Metallo-
proteases are synthesised as proenzymes and are activated by
proteolytic cleavage, which removes an inhibitory peptide.
Their activity is further regulated by specific inhibitory
molecules, tissue inhibitors of metalloproteases (TIMPs), of
which two family members have been identified, and these
have different substrate specificities. TIMP-1 and -2 are able
to inhibit tumour metastasis in several model systems and,
therefore, provide potential molecules upon which anti-
metastasis agents can be designed.
A potential anti-cancer therapy that is already in clinical
trial is based upon the blockade of the epidermal growth
factor receptor (EGFR), which has been shown to be over-
expressed in many squamous cell tumours. John Mendelsohn
(New York) has developed two monoclonal antibodies which
bind EGFR with high affinity and block EGF binding and
its resulting tyrosine kinase activity. Ligand-dependent pro-
liferation of cell lines expressing EGFR is inhibited by these
antibodies, as is the growth of human tumour xenografts,
outlining the enormous potential of these antibodies as anti-
tumour agents. However, well-established tumours are
relatively insensitive to this therapy. This problem has been
overcome in murine tumour models, in which well-
established tumours regress when treated with antibodies in
combination with doses of other anti-cancer agents such as
cisplatinum, doxorubicin or taxol, which on their own are
ineffective. In phase I clinical trials both monoclonal
antibodies appear not to produce any adverse toxic reactions
and hopefully they will prove to be useful clinical drugs.
p21ras proteins are members of a large family of GTP-
binding proteins involved in a variety of cellular functions.
They are capable of transforming mammalian cells, and it
has been estimated that mutant p2lras proteins have a
causative role in about 30% of all human tumours. It is now
clear that p2lras is required for mitogenic signalling by
tyrosine kinase growth factor receptors and their oncoprotein
counterparts, and at least part of the ras protein function is
in the activation of the raf-Map kinase kinase-Map kinase
pathway. Map kinase (MapK) is known to enter the nucleus
where several transcription factors are substrates, thus a
pathway linking growth factor stimulation at the cell mem-
brane to changes in gene expression has been delineated.
Chris Marshall (London) discussed the fact that yeast prob-
ably utilise similar signalling pathways as higher eukaryotes
since yeast homologues to MapKK and MapK have been
isolated. Furthermore, he showed that yeast MapKK lies
upstream of yeast MapK and provided convincing evidence
that the yeast and higher eukaryotic enzymes are functionally
homologous. This is an extremely important finding since the
availability of yeast strains expressing a functional mam-
malian signalling pathway will be of use in further delineat-
ing the signalling pathway and in the screening of useful
inhibitory agents.
Summary
About 80% of neoplasias are epithelial in origin and, as
such, understanding the molecular mechanisms involved in
the development of epithelial tumours is vital to the diag-
nosis, prognosis and treatment of the vast majority of human
cancers. Obviously this is no easy task but, as outlined
above, great efforts are being made to identify important
molecules involved in the progression of normal epithelial
cells to carcinoma. The development of techniques to identify
new oncogenes is of particular importance, and hopefully the
cDNA expression cloning system of Stuart Aaronson will be
a useful tool in this respect. The potential of some of these
molecules to be used as therapeutic targets will require the
development of suitable screening procedures, such as that
being established by Chris Marshall for the ras-Map kinase
pathway in yeast. It is encouraging that the immune response
to virally (HPV) induced cancer is being carefully elucidated
and the prospects of vaccine development for the treatment
of cervical cancer coming nearer since this particular form of
SCC is a major cancer globally. Finally it was fitting to end
the meeting on an optimistic note with John Mendelsohn's
EGFR monoclonal antibody therapy entering clinical trials,
and hopefully this will prove efficacious in the treatment of
human SSC.